Physician profile
Lacey D Sanchez
NPI 1841570272
$3,180.50
in general payments reported to CMS, 2019-2025
17 companies · $569 in 2025
The $569 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $428 · 2022: $289 · 2023: $1,038 · 2024: $856 · 2025: $569.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.04 |
| Education | $212.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $949.52 | 2021-2025 | Fasenra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $563.24 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $539.95 | 2023-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $210.91 | 2022-2025 | Hyqvia, Takhzyro, Cuvitru |
| Incyte Corporation | $179.19 | 2021-2025 | Opzelura |
| Genzyme Corporation | $169.18 | 2021-2024 | |
| Kaleo, INC. | $121.72 | 2022-2024 | Auvi-Q |
| Abbvie INC. | $81.38 | 2022-2023 | |
| Csl Behring | $77.76 | 2024-2025 | Hizentra |
| Pfizer INC. | $48.64 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $47.11 | 2025 | Neffy |
| Optinose US, INC. | $39.69 | 2021-2022 | |
| Lilly USA, LLC | $38.57 | 2025 | Ebglyss |
| Novartis Pharmaceuticals Corporation | $35.64 | 2025 | |
| Amgen INC. | $34.00 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $30.34 | 2023-2025 | Xembify, Gamunex-C |
| Genentech USA, INC. | $13.66 | 2024 | Xolair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacey Sanchez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.